Granell, MiquelCalvo, XavierGarcia Guinon, AntoniEscoda, LourdesAbella, EugèniaMartinez, Clara MªTeixido, MontserratGimenez, Mª TeresaSenín, AliciaSanz, PatriciaCampoy, DesiréeVicent, AnaArenillas, LeonorRosiñol Dachs, LauraSierra, JorgeBladé, J. (Joan)Fernández de Larrea Rodríguez, Carlos JoséGEMMAC (Grup per l'estudi del mieloma i l'amiloïdosi de Catalunya)2026-01-282026-01-282017-06-010390-6078https://hdl.handle.net/2445/226357The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×109/L vs 214×109/L, P<0.0001) and higher bone marrow plasma cells (median 53% vs 36%, P=0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.6 p.application/pdfengcc-by-nc (c) Granell, Miquel et al., 2017https://creativecommons.org/licenses/by-nc/4.0/LeucèmiaDiagnòsticMedul·la òssiaLeukemiaDiagnosisBone marrowinfo:eu-repo/semantics/article7447322026-01-28info:eu-repo/semantics/openAccess284094828255016